Natixis Advisors
RCUS icon

Natixis Advisors’s Arcus Biosciences RCUS Stock Holding History

Natixis Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
+12,267
New +$303K ﹤0.01% 1753

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Natixis Advisors's RCUS Position: Q2 2026 in Review

Natixis Advisors opened a new position in Arcus Biosciences (RCUS) in Q2 2026: 12,267 shares worth $378K. The stake represents ﹤0.01% of the portfolio and ranks #1753 among its holdings.

229 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Natixis Advisors held 12,267 shares of Arcus Biosciences worth $378K as of Q2 2026.
  • Arcus Biosciences was a new Natixis Advisors position in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1753 holding.
  • 229 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.